Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crizanlizumab - Novartis

Next Previous
Drug Profile

Crizanlizumab - Novartis

Alternative Names: Adakveo; Crizanlizumab-tmca - Novartis; SEG-101; Sel G1

Latest Information Update: 11 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Selexys Pharmaceuticals
  • Developer Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Vaso-occlusive crisis
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Vaso-occlusive crisis
  • Phase II Priapism
  • Phase I/II Myelofibrosis

Most Recent Events

  • 11 Dec 2019 Novartis announces intention to launch Crizanlizumab for Sickle cell anaemia
  • 27 Nov 2019 Novartis Pharmaceuticals initiates enrolment in the phase II STEADFAST trial in chronic kidney disease caused by sickle cell nephropathy (In adolescents, In adults, In the elderly) in Spain (IV) (NCT04053764)
  • 15 Nov 2019 Registered for Vaso-occlusive crisis in patients with sickle cell anaemia (Prevention, In adolescents, In adults) in USA (IV) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top